Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="BERTRAND, Y" or (type any "bookEditor journalEditor issueEditor" and editor="BERTRAND, Y")

Add to list
Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia : results of the EORTC CLG 58881 and 58951 trials

C Piette, S Suciu, E Clappier, Y Bertrand, S Drunat, S Girard, K Yakouben, G Plat, N Dastugue, F Mazingue, et al.

(2018) LEUKEMIA. 32(1). p.244-248
Add to list
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Chrildren's Leukemia Group study 58951

E Clappier, N Grardel, M Bakkus, J Rapion, Barbara De Moerloose (UGent) , P Kastner, A Caye, J Vivent, V Costa, A Ferster, et al.

(2015) LEUKEMIA. 29(11). p.2154-2161
Add to list
An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions

E Clappier, M-F Auclerc, J Rapion, M Bakkus, A Caye, A Khemiri, C Giroux, L Hernandez, E Kabongo, S Savola, et al.

(2014) LEUKEMIA. 28(1). p.70-77
Add to list
- Journal Article
- A1
Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies

A Renneville, S Kaltenbach, E Clappier, S Collette, JB Micol, B Nelken, P Lepelley, N Dastugue, Yves Benoit (UGent) , Y Bertrand, et al.

(2010) LEUKEMIA. 24(2). p.476-480
Add to list
- Conference Paper
- C3
Presentation and outcome of children with down syndrome and acute lymphoblastic leukemia in the eortc children's leukemia group protocol 58951

Veerle Mondelaers (UGent) , Barbara De Moerloose (UGent) , S Suciu, A Ferster, P Lutz, A Uyttebroeck, D Plantaz, L Norton, N Sirvent, A Robert, et al.

(2010) HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 95(Suppl. 2). p.260-260
Add to list
NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951

E Clappier, S Collette, N Grardel, S Girard, L Suarez, G Brunie, S Kaltenbach, K Yakouben, F Mazingue, A Robert, et al.

(2010) LEUKEMIA. 24(12). p.2023-2031
Add to list
- Conference Paper
- C3
Prognostic significance of blasts with/without pleiocytosis in the cerebro-spinal fluid (CSF) of children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) children leukemia group study 58881

N Sirvent, S Suciu, X Rialland, A Robert, F Mazingue, F Millot, Barbara De Moerloose (UGent) , A Ferster, P Rohrlich, L Norton, et al.

(2006) Blood. 108(11). p.A149-A149
Add to list
- Journal Article
- A1
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report

N ENTZ-WERLE, S SUCIU, JD TEN BOSCH, E VILMER, Y BERTRAND, Yves Benoit (UGent) , G MARGUERITTE, E PLOUVIER, P BOUTARD, Els Vandecruys (UGent) , et al.

(2005) LEUKEMIA. 19(12). p.2072-2081
Add to list
- Journal Article
- A1
Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951

H CAVÉ, S SUCIU, C PREUDHOMME, Bruce Poppe (UGent) , A ROBERT, A UYTTEBROECK, M MALET, P BOUTARD, Yves Benoit (UGent) , L MAUVIEUX, et al.

(2004) BLOOD. 103(2). p.442-450
Add to list
- Conference Paper
- C3
HOX11L2 expression linked to t(5;14)(q35;q32) is not associated with poor prognosis in childhood T-ALL treated in EORTC trials 58 881 and 58 951

H CAVÉ, S SUCIU, C PREUDHOMME, Bruce Poppe (UGent) , A ROBERT, A UYTTEBROEK, M MALET, P BOUTARD, Yves Benoit (UGent) , L MAUVIEUX, et al.

(2002) BLOOD. 100(11).

Academic Bibliography

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia : results of the EORTC CLG 58881 and 58951 trials

IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Chrildren's Leukemia Group study 58951

An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions

Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies

Presentation and outcome of children with down syndrome and acute lymphoblastic leukemia in the eortc children's leukemia group protocol 58951

NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951

Prognostic significance of blasts with/without pleiocytosis in the cerebro-spinal fluid (CSF) of children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) children leukemia group study 58881

Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report

Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951

HOX11L2 expression linked to t(5;14)(q35;q32) is not associated with poor prognosis in childhood T-ALL treated in EORTC trials 58 881 and 58 951

Contents

Support

Contact